
William R Strohl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6353692/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. BioDrugs, 2022, 36, 231-323.	2.2	24
2	Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies, 2019, 8, 41.	1.2	90
3	Identification of biologic agents to neutralize the bicomponent leukocidins of <i>Staphylococcus aureus</i> . Science Translational Medicine, 2019, 11, .	5.8	22
4	Current progress in innovative engineered antibodies. Protein and Cell, 2018, 9, 86-120.	4.8	217
5	Frontiers and Opportunities: Highlights of the 2nd Annual Conference of the Chinese Antibody Society. Antibody Therapeutics, 2018, 1, 27-36.	1.2	15
6	Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. BioDrugs, 2017, 31, 317-334.	2.2	773
7	Chimeric Genes, Proteins â~†. , 2017, , .		1
8	Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections. Trends in Pharmacological Sciences, 2016, 37, 231-241.	4.0	93
9	Optimizing production of Fc-amidated peptides by Chinese hamster ovary cells. BMC Biotechnology, 2015, 15, 95.	1.7	5
10	A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies. Molecular Cancer Therapeutics, 2015, 14, 681-691.	1.9	18
11	An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs, 2015, 7, 494-504.	2.6	32
12	Trastuzumab Triggers Phagocytic Killing of High HER2 Cancer Cells In Vitro and In Vivo by Interaction with Fcl ³ Receptors on Macrophages. Journal of Immunology, 2015, 194, 4379-4386.	0.4	150
13	Secretion of Fc-amidated peptide fusion proteins by Chinese hamster ovary cells. BMC Biotechnology, 2015, 15, 61.	1.7	5
14	Dysfunctional Antibodies in the Tumor Microenvironment Associate with Impaired Anticancer Immunity. Clinical Cancer Research, 2015, 21, 5380-5390.	3.2	19
15	Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs, 2015, 29, 215-239.	2.2	320
16	An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods, 2014, 65, 114-126.	1.9	127
17	Potential therapeutic roles for antibody mixtures. Expert Opinion on Biological Therapy, 2013, 13, 1347-1352.	1.4	13
18	Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions. Journal of Biological Chemistry, 2013, 288, 30843-30854.	1.6	33

WILLIAM R STROHL

#	ARTICLE	IF	CITATIONS
19	Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor $\hat{I}\pm1$. Biochemical Journal, 2013, 451, 165-175.	1.7	11
20	Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function. Journal of Immunology, 2012, 189, 5457-5466.	0.4	97
21	A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Research, 2012, 14, R116.	2.2	53
22	An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes. International Journal of Biological Sciences, 2012, 8, 310-327.	2.6	91
23	Therapeutic antibody engineering. , 2012, , .		51
24	Isotype Selection and Fc Engineering: Design and Construction of Fit-for-Purpose Therapeutic Antibodies. Modecular Medicine and Medicinal, 2011, , 147-220.	0.4	3
25	A Rate-Limiting Role for Dickkopf-1 in Bone Formation and the Remediation of Bone Loss in Mouse and Primate Models of Postmenopausal Osteoporosis by an Experimental Therapeutic Antibody. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 568-578.	1.3	73
26	Generation and Selection of Novel Fully Human Monoclonal Antibodies That Neutralize Dickkopf-1 (DKK1) Inhibitory Function in Vitro and Increase Bone Mass in Vivo. Journal of Biological Chemistry, 2010, 285, 40135-40147.	1.6	89
27	IgG2m4, an engineered antibody isotype with reduced Fc function. MAbs, 2009, 1, 572-579.	2.6	85
28	Evidence that inhibition of insulin receptor signaling activity by PC-1/ENPP1 is dependent on its enzyme activity. European Journal of Pharmacology, 2009, 606, 17-24.	1.7	26
29	Suppression of PC-1/ENPP-1 expression improves insulin sensitivity in vitro and in vivo. European Journal of Pharmacology, 2009, 616, 346-352.	1.7	30
30	Optimization of Fc-mediated effector functions of monoclonal antibodies. Current Opinion in Biotechnology, 2009, 20, 685-691.	3.3	151
31	Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs, 2009, 1, 462-474.	2.6	20
32	<i>Short Communication: In Vitro</i> Synergy between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 gp41. AIDS Research and Human Retroviruses, 2008, 24, 1537-1544.	0.5	16
33	Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays. Journal of Immunological Methods, 2007, 322, 94-103.	0.6	11
34	A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 14759-14764.	3.3	136